[ad_1]
Working EBITDA in the course of the interval got here in at Rs 825 crore, up 22 per cent YoY. Within the Q2 interval of the earlier fiscal, operation profitability was at Rs 679 crore.
)
Market outperformance was led by continued double digit development in power therapies, revival in gastro demand, traction in client division, and new launches.
[ad_2]